JP2011504092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504092A5 JP2011504092A5 JP2010530629A JP2010530629A JP2011504092A5 JP 2011504092 A5 JP2011504092 A5 JP 2011504092A5 JP 2010530629 A JP2010530629 A JP 2010530629A JP 2010530629 A JP2010530629 A JP 2010530629A JP 2011504092 A5 JP2011504092 A5 JP 2011504092A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- antibody
- composition
- fragment
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 86
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 102000001708 Protein Isoforms Human genes 0.000 claims description 27
- 108010029485 Protein Isoforms Proteins 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 22
- 230000000890 antigenic effect Effects 0.000 claims description 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 18
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 18
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 13
- 230000002491 angiogenic effect Effects 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 10
- 230000033115 angiogenesis Effects 0.000 claims description 9
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 239000013074 reference sample Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001023 pro-angiogenic effect Effects 0.000 claims 1
- 206010071989 Vascular endothelial growth factor overexpression Diseases 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98243807P | 2007-10-25 | 2007-10-25 | |
| PCT/IL2008/001410 WO2009053987A1 (en) | 2007-10-25 | 2008-10-26 | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011504092A JP2011504092A (ja) | 2011-02-03 |
| JP2011504092A5 true JP2011504092A5 (enExample) | 2012-11-15 |
Family
ID=40385456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530629A Pending JP2011504092A (ja) | 2007-10-25 | 2008-10-26 | 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8592563B2 (enExample) |
| EP (1) | EP2203480A1 (enExample) |
| JP (1) | JP2011504092A (enExample) |
| CN (1) | CN101970486A (enExample) |
| AU (1) | AU2008315414A1 (enExample) |
| CA (1) | CA2703154A1 (enExample) |
| WO (1) | WO2009053987A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| AU2010339723B2 (en) * | 2009-12-21 | 2014-11-06 | Mayo Foundation For Medical Education And Research | Early marker of proteinuria in patients treated with an anti-VEGF treatment |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| MX343117B (es) * | 2011-06-15 | 2016-10-25 | Hoffmann La Roche | Anticuerpos del receptor eritropoyetina (epo) anti-humana y metodos de uso. |
| HRP20190044T1 (hr) | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| US20150353617A1 (en) * | 2013-01-27 | 2015-12-10 | The Cleveland Clinic Foundation | Anti-angiogenic vegf-ax isoform |
| MX382902B (es) | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| WO2016194708A1 (ja) * | 2015-05-29 | 2016-12-08 | 国立大学法人名古屋大学 | 尿中ＶＥＧＦ－Ａ１６５ｂを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体 |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6022541A (en) * | 1991-10-18 | 2000-02-08 | Beth Israel Deaconess Medical Center | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| JP4689956B2 (ja) * | 2001-08-01 | 2011-06-01 | ユニバーシティ オブ ブリストル | 増殖因子イソ型 |
| US20050009110A1 (en) * | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| US20060286636A1 (en) * | 2005-04-29 | 2006-12-21 | Shima David T | VEGF variants |
| US20080031815A1 (en) * | 2006-07-27 | 2008-02-07 | Xiaoyuan Chen | Pet imaging of vascular endothelial growth factor receptor (VEGFR), compositions for VEGF cancer imaging, and methods of VEGF cancer imaging |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
-
2008
- 2008-10-26 AU AU2008315414A patent/AU2008315414A1/en not_active Abandoned
- 2008-10-26 JP JP2010530629A patent/JP2011504092A/ja active Pending
- 2008-10-26 WO PCT/IL2008/001410 patent/WO2009053987A1/en not_active Ceased
- 2008-10-26 US US12/739,619 patent/US8592563B2/en not_active Expired - Fee Related
- 2008-10-26 CA CA2703154A patent/CA2703154A1/en not_active Abandoned
- 2008-10-26 CN CN2008801226493A patent/CN101970486A/zh active Pending
- 2008-10-26 EP EP08842953A patent/EP2203480A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504092A5 (enExample) | ||
| AU2017200281B2 (en) | S100a4 antibodies and therapeutic uses thereof | |
| AU2015253915B2 (en) | Antibody binding to FcRn for treating autoimmune diseases | |
| DK2888283T3 (en) | ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE | |
| EP3381940B1 (en) | Anti-ang2 antibody | |
| CN102741292B (zh) | 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体 | |
| KR102405278B1 (ko) | Alk7 결합 단백질 및 이들의 용도 | |
| JP2010527939A5 (enExample) | ||
| CN112955748A (zh) | 治疗癌症的方法 | |
| KR102715157B1 (ko) | Il-17c에 대한 항체 | |
| WO2018067819A1 (en) | Compositions and methods for treatment of cancers | |
| WO2018031865A1 (en) | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor | |
| CN105849125B (zh) | 神经调节蛋白变构抗her3抗体 | |
| WO2020228604A1 (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| WO2014175444A1 (ja) | 抗ｎｌｒｒ１抗体 | |
| US10393748B2 (en) | Method for predicting efficacy of c-Met inhibitor | |
| US20170137523A1 (en) | Therapy for gist | |
| US10472682B2 (en) | Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF | |
| JP2022502434A (ja) | がんの治療用の薬学的組合せ | |
| CN120035606A (zh) | 一种治疗实体瘤的方法 | |
| WO2025255282A1 (en) | Anti-cdh17 binding molecules | |
| WO2023089131A1 (en) | Treatment and diagnosis of diseases associated to pathogenic fibrosis | |
| CN121108355A (zh) | 抗amhr2×cd3双特异性抗体及制备方法和应用 | |
| Bhatia et al. | 079 Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus vulgaris treated with steroid sparing agents or rituximab | |
| HK40013319A (en) | Anti-cd47 antibody and use thereof |